معرفی
Otis Brawley, MD, is a Bloomberg Distinguished Professor and Professor in the Department of Epidemiology at the Johns Hopkins Bloomberg School of Public Health. He also serves as Vice Chair for IDARE (Inclusion, Diversity, Anti-Racism, and Equity) in the same department, reflecting his leadership in advancing equity in cancer research and public health.
Dr. Brawley earned his BS and MD from the University of Chicago in 1981 and 1985, respectively. His academic journey has positioned him as a leading voice in cancer epidemiology and public health policy.
His research is centered on cancer epidemiology, with a strong emphasis on cancer screening, racial disparities in cancer outcomes, prostate and breast cancer, and the design and infrastructure of clinical trials. His work bridges clinical medicine and population health, aiming to improve cancer prevention and equity in healthcare delivery.
The recent publications (2024–2025) highlight his engagement with pressing issues in oncology, including the impact of the COVID-19 pandemic on cancer trends, the need for a robust national clinical trial infrastructure, and the use of remote monitoring in decentralized trials. A recurring theme is the examination of race and health disparities, particularly in prostate cancer, underscoring his commitment to health equity.
While specific scientific awards are not listed in the provided text, his editorial contributions to major journals such as Cancer, JAMA Health Forum, and JAMA Network Open reflect recognition as a thought leader in the field.
Dr. Brawley is actively involved in advising and research collaboration, as evidenced by his co-authorship on numerous peer-reviewed articles. Although specific grants or funding sources are not detailed, his role in shaping national clinical trial policy suggests significant influence on research funding and priorities. He is also engaged in academic teaching, as indicated by his involvement in the Cancer Epidemiology Prevention and Control Seminars at Johns Hopkins.
His work is highly collaborative, involving partnerships across institutions and disciplines, particularly in efforts to increase minority enrollment in clinical trials and improve data collection methods. These collaborations reflect a team-based approach to addressing complex public health challenges in oncology.
